Kyrgyzstan
Tuberculosis profile
| High MDR-TB burden |
Population  2012 5.5 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.52 (0.51–0.53) 9.5 (9.3–9.8)
Mortality (HIV+TB only) 0.059 (0.046–0.072) 1.1 (0.85–1.3)
Prevalence  (includes HIV+TB) 12 (5.5–21) 217 (101–376)
Incidence  (includes HIV+TB) 7.7 (6.4–9.2) 141 (116–168)
Incidence (HIV+TB only) 0.29 (0.24–0.34) 5.3 (4.4–6.3)
Case detection, all forms (%) 80 (67–97)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 594 (27) Relapse 344 (32)
Smear-negative 2 448 (42) Treatment after failure 0 (0)
Smear-unknown / not done 0 (0) Treatment after default 0 (0)
Extrapulmonary 1 809 (31) Other 721 (68)
Other          
Total new 5 851   Total retreatment 1 065  
           
Other (history unknown) 0        
Total new and relapse 6 195   Total cases notified 6 916  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6 1.5 1.2
Age < 15 12 111 517
Laboratories 2012
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 10.0
Drug susceptibility testing (per 5 million population) 2.7
Is second-line drug susceptibility testing available? Yes, in and outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 78   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 56  
TB/HIV 2012 Number (%)
TB patients with known HIV status 6 916 (100)
HIV-positive TB patients 151 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 101 (67)
HIV-positive TB patients on antiretroviral therapy (ART) 118 (78)
HIV-positive people screened for TB 1 316  
HIV-positive people provided with IPT 5  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 26 (23–30) 68 (65–72)
MDR-TB cases among notified pulmonary
TB cases
1 100 (910–1 200) 730 (690–770)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 1 659 (99%) 831 (78%) 2 754
Laboratory-confirmed MDR-TB cases 433 453 958
Patients started on MDR-TB treatment     775
Financing TB control 2013
National TB programme budget (US$ millions) 35
% Funded domestically 40%
% Funded internationally 57%
% Unfunded 3%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data